12 giugno 2019

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

– The main results from PIONEER 6 were presented today at the American Diabetes Association (ADA) 79th Scientific Sessions and simultaneously published in The New England Journal of Medicine (NEJM)1,2. Oral semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analogue in a pill. 
The MACE […]

11 giugno 2019